CapyFin

Calendar Reports

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

GoodRx Fiscal Q3 2020 Earnings Report - CapyFin

GoodRx

GDRX · NASDAQ🇺🇸

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 +1.84%Q2 2025 -20.69%Q1 2025 +11.90%Q4 2024 +1.84%Q3 2024 -19.97%Q2 2024 -16.26%Q1 2024 -13.27%Q4 2023 +29.06%Q3 2023 -12.43%Q2 2023 -5.61%Q1 2023 +7.04%Q4 2022 +5.57%Q3 2022 -21.47%Q2 2022 +10.47%Q1 2022 -37.44%Q4 2021 -36.33%Q3 2021 -5.73%Q2 2021 +19.96%Q1 2021 +5.05%Q4 2018 -10.46%Q2 2020 -3.87%Q4 2020 -3.87%Q1 2020 -7.34%Q3 2019 -7.34%Q3 2020 -7.34%Q4 2019 -7.34%Q2 2019 Q1 2019

Nov 12, 2020

•

Sep 30, 2020

GoodRx Q3 2020 Earnings Report

Previous year: $266M

Previous year: $0.14

Monthly Active Consumers

Subscription Plans

Previous year: $98.3M

Cash and Equivalents

Previous year: $59.7M

Previous year: $65.8M

GoodRx

Unlock previous datapoints

GoodRx

Unlock previous datapoints

Revenue by Segment

Prescription Transactions Revenue

Unlock previous datapoints

CapyFin.com

Subscription Revenue

Unlock previous datapoints

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

GoodRx Revenue by Segment